ADCs Show Promise in Leukemias.
نویسنده
چکیده
According to a phase III study, the antibody-drug conjugate inotuzumab ozogamicin is more likely to induce complete remissions, with full or incomplete hematologic recovery, in patients with relapsed or refractory acute lymphocytic leukemia. Data from a phase I study of another antibody-drug conjugate, vadastuximab talirine, demonstrates that it is safe and effective against acute myeloid leukemia.
منابع مشابه
Implementing Plug-and-Play Concepts in the Development of an Attitude Determination and Control System to Support Operationally Responsive Space
Operationally Responsive Space (ORS) has become the mantra for the next generation spacecraft that will support the warfighter. ORS missions require an extension of the current, traditional approach for fine-tuned, high cost, high accuracy attitude determination and control system (ADCS) software to create an ADCS system that can be developed much faster and less expensively. To achieve this fa...
متن کاملHigh-Speed and Low-Power Flash ADCs Encoder
This paper presents a high-speed, low-power and low area encoder for implementation of flash ADCs. Key technique for design of this encoder is performed by convert the conventional 1-of-N thermometer code to 2-of-M codes (M = ¾ N). The proposed encoder is composed from two-stage; in the first stage, thermometer code are converted to 2-of-M codes by used 2-input AND and 4-i...
متن کاملLinked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent ...
متن کاملFcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Fc receptor-like 5 (FcRL5/FcRH5/IRTA2/CD307) is a surface protein expressed selectively on B cells and plasma cells. We found that FcRL5 was expressed at elevated levels on the surface of plasma cells from the bone marrow of patients diagnosed with multiple myeloma. This prevalence in multiple myeloma and narrow pattern of normal expression indicate that FcRL5 could be a target for antibody-bas...
متن کاملAntibody Therapy for Pediatric Leukemia
Despite increasing cure rates for pediatric leukemia, relapsed disease still carries a poor prognosis with significant morbidity and mortality. Novel targeted therapies are currently being investigated in an attempt to reduce adverse events and improve survival outcomes. Antibody therapies represent a form of targeted therapy that offers a new treatment paradigm. Monoclonal antibodies are activ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cancer discovery
دوره 6 9 شماره
صفحات -
تاریخ انتشار 2016